QTTB

Q32 Bio Inc

9.34

Nov 10 • 4:59 AM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: NKTR ACRS EVMN ZURA ANAB ALMS IMA ARQT INCY LLY

| Held by: VTI AVUV VXF FDM DFAS DFAT AVSC IWC AVUS ROSC

Index	-
Market Cap	279.49M
Enterprise Value	-4.98M
Income	32.25M
Sales	53.74M
Book/sh	9.62
Cash/sh	9.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	24
IPO	Mar 28, 2018

P/E	2.79
Forward P/E	-
PEG	-
P/S	5.20
P/B	0.97
P/C	0.97
P/FCF	-
EV/EBITDA	-0.27
EV/Sales	-0.09
Quick Ratio	56.33
Current Ratio	56.33
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	3.34
EPS next Y	-2.07
EPS next Q	-0.28
EPS this Y	-156.40%
EPS next Y	-51.56%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	155.87% 81.85%
EPS Y/Y TTM	197.18%
Sales Y/Y TTM	-
EPS Q/Q	56.56%
Sales Q/Q	-
Earnings	Nov 04 BMO
EPS/Sales Surpr.	20.42% -

Insider Own	35.34%
Insider Trans	54.44%
Inst Own	58.95%
Inst Trans	14.63%
ROA	18.17%
ROE	23.96%
ROIC	11.04%
Gross Margin	99.35%
Oper. Margin	34.20%
Profit Margin	60.02%
SMA20	7.95%
SMA50	-1.62%
SMA200	-0.80%
Trades

Shs Outstand	29.89M
Shs Float	19.35M
Short Float	29.21%
Short Ratio	8.24
Short Interest	5.65M
52W High	23.57 -60.37%
52W Low	1.90 390.29%
Volatility	6.73% 6.71%
ATR (14)	0.56
RSI (14)	54.89
Beta	0.44
Rel Volume	0.01
Avg Volume	686.19K
Volume	399

Perf Week	6.62%
Perf Month	6.86%
Perf Quarter	-39.23%
Perf Half Y	60.76%
Perf YTD	181.33%
Perf Year	284.36%
Perf 3Y	-48.62%
Perf 5Y	-91.35%
Perf 10Y	-
Recom	1.00
Target Price	39.43
Prev Close	9.34
Price	9.34
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$39.43

Implied Upside

+322.2%

Analysts13incl. previous ratings

Rating Distribution7 Buy · 6 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 12, 2026	Initiated	LLeerink Partners	Outperform	$40	+328.3%
Sep 28, 2026	Initiated	JJefferies	Buy	$29	+210.5%
Aug 24, 2026	Initiated	MMorgan Stanley	Overweight	$34	+264.0%
May 18, 2026	Initiated	CCantor Fitzgerald	Overweight
Feb 25, 2026	Initiated	HH.C. Wainwright	Buy	$13	+39.2%
Feb 11, 2025	Downgrade	PPiper Sandler	Overweight → Neutral	$20 → $4	-57.2%
Feb 11, 2025	Downgrade	BBMO Capital Markets	Outperform → Market Perform	$22 → $3	-67.9%
Dec 11, 2024	Downgrade	WWells Fargo	Overweight → Equal Weight	$95 → $16	+71.3%
Dec 11, 2024	Downgrade	RRaymond James	Strong Buy → Outperform	$90 → $22	+135.5%
Dec 11, 2024	Downgrade	LLeerink Partners	Outperform → Market Perform	$68 → $9	-3.6%
Dec 11, 2024	Downgrade	GGuggenheim	Buy → Neutral
Dec 06, 2024	Initiated	BBMO Capital Markets	Outperform	$64	+585.2%
Oct 24, 2024	Initiated	RRaymond James	Strong Buy	$90	+863.6%
Sep 11, 2024	Initiated	WWells Fargo	Overweight	$95	+917.1%
Jun 17, 2024	Initiated	GGuggenheim	Buy	$100	+970.7%
May 21, 2024	Initiated	LLeerink Partners	Outperform	$54	+478.2%
Apr 11, 2024	Initiated	OOppenheimer	Outperform	$50	+435.3%
Apr 02, 2024	Initiated	PPiper Sandler	Overweight	$45	+381.8%
Jul 28, 2023	Downgrade	RRobert W. Baird	Outperform → Neutral	$9 → $1.50	-83.9%
Feb 22, 2022	Reiterated	BBTIG Research	Neutral	$35 → $29	+210.5%

Nov-04-26 07:11AM	Q32 Bio: Q3 Earnings Snapshot (Associated Press)
06:59AM	Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
Oct-01-26 11:45AM	Nektar Stock Sinks Despite Promising Hair Loss Treatment Data (Barrons.com)
Sep-30-26 09:15AM	Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 (PR Newswire) -13.22%
Sep-21-26 09:15AM	Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 (PR Newswire)
06:59AM	Loading…
Sep-14-26 06:59AM	Q32 Bio Appoints Jose Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer (PR Newswire)
Sep-01-26 06:59AM	Q32 Bio to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-05-26 07:15AM	Q32 Bio: Q2 Earnings Snapshot (Associated Press)
06:59AM	Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
Jul-14-26 10:58PM	Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire) -13.66% -14.95%
09:04AM	Q32 Bio stock surges 83% on positive alopecia drug trial data (Quartz)
Jul-13-26 10:14PM	Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today? (Stocktwits) +90.72%
05:00PM	QTTB Stock Clocks Best Day In A Year Following Positive Alopecia Data Analyst Sees Further 200% Upside (Stocktwits)
04:01PM	Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
08:24AM	Q32 Bio Shares Jump 60% After Positive Mid-Stage Alopecia Trial Results (QTTB) (Investors Hub)
08:03AM	Loading…
08:03AM	Q32 bounces back to claim study success for alopecia drug (BioPharma Dive)
06:59AM	Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata (PR Newswire)
Jul-10-26 04:05PM	Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 (PR Newswire) -10.96%
May-27-26 01:55PM	QTTB Stock Hits 18-Month High, Heads Toward Recording Its Best Ever Month Whats Driving The Investor Optimism? (Stocktwits) +81.24%
11:53AM	Q32 Bio Secures $55 Million Private Placement to Advance Alopecia Areata Pipeline (QTTB) (InvestorsHub)
08:00AM	Q32 Bio Announces $55 Million Private Placement Financing (PR Newswire)
May-05-26 07:05AM	Q32 Bio: Q1 Earnings Snapshot (Associated Press)
06:59AM	Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
Apr-08-26 06:59AM	Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference (PR Newswire) -7.29%
Mar-10-26 07:14AM	Q32 Bio: Q4 Earnings Snapshot (Associated Press Finance) +17.45%
06:59AM	Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Mar-01-26 12:34PM	Q32 Bio Spotlights Bempikibart AA Data Ahead, Sharpens Focus After Asset Sale at Oppenheimer Confab (MarketBeat)
Feb-18-26 06:59AM	Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (PR Newswire) -5.37%
Feb-17-26 06:59AM	Q32 Bio Announces $10.5 Million Registered Direct Offering (PR Newswire) +9.74%
Dec-02-25 11:28AM	This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? (Barchart) -10.73%
07:00AM	Loading…
Dec-01-25 07:00AM	Q32 Bio Sells Complement Inhibitor ADX-097 (PR Newswire) +74.43%
Nov-13-25 07:04AM	Q32 Bio: Q3 Earnings Snapshot (Associated Press Finance) -9.05%
06:59AM	Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Oct-21-25 06:59AM	Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata (PR Newswire) -10.81%
Aug-28-25 06:59AM	Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference (PR Newswire)
Aug-06-25 07:04AM	Q32 Bio: Q2 Earnings Snapshot (Associated Press Finance)
06:59AM	Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Jun-25-25 06:59AM	Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer (PR Newswire)
Jun-24-25 01:06PM	Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary (TipRanks)
Jun-23-25 07:00AM	OXB completes acquisition of remaining stake in US subsidiary (GlobeNewswire)
May-08-25 06:59AM	Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Apr-30-25 06:59AM	Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata (PR Newswire)
Apr-16-25 06:59AM	Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata (PR Newswire) -8.19%
Apr-08-25 12:00PM	All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy (Zacks) -5.23%
Mar-11-25 06:59AM	Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) -7.77%
Mar-08-25 11:00AM	Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting (PR Newswire)
Feb-28-25 09:00AM	Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting (PR Newswire)
Feb-26-25 06:59AM	Q32 Bio to Participate in Upcoming March Investor Conferences (PR Newswire) -5.26%
Feb-10-25 04:05PM	Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata (PR Newswire) -9.43%
Feb-04-25 04:05PM	Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference (PR Newswire) +7.95%
Dec-12-24 07:45AM	Q32 Bio price target lowered to $20 from $80 at Oppenheimer (TipRanks) -28.57%
Dec-11-24 04:11PM	Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment (Investor's Business Daily) -75.62%
09:42AM	Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment (Investor's Business Daily)
Dec-10-24 04:05PM	Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program (PR Newswire) +7.68%
Nov-07-24 06:59AM	Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-05-24 06:59AM	Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (PR Newswire)
Oct-14-24 06:59AM	Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 (PR Newswire)
Aug-29-24 06:59AM	Q32 Bio to Participate in Upcoming September Investor Conferences (PR Newswire)
Jul-09-24 06:59AM	Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis (PR Newswire) +7.89%
Jul-01-24 06:59AM	Q32 Bio Joins Russell 3000 Index (PR Newswire) +5.74%
May-09-24 01:56PM	QTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024 (InvestorPlace)
06:59AM	Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Apr-03-24 07:00AM	Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer (PR Newswire)
Mar-18-24 04:30PM	Homology Medicines Declares Distribution to Common Stockholders (GlobeNewswire)
Mar-15-24 09:52PM	FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023 (InvestorPlace)
Mar-01-24 10:48AM	Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm (GlobeNewswire)
Jan-27-24 12:10PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates EGLE, FRLN, ROVR, FIXX (GlobeNewswire)
Jan-03-24 04:08PM	Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) +5.43%
Nov-17-23 06:40AM	Q32 Bio to merge with Homology Medicines (Pharmaceutical Business Review)
Nov-16-23 12:18PM	Homology enters reverse merger with Q32 Bio (BioPharma Dive) -34.99%
07:05AM	Q32 Bio and Homology Medicines Announce Merger Agreement (PR Newswire)
Nov-14-23 05:02PM	Homology Medicines: Q3 Earnings Snapshot (Associated Press Finance) -13.74%
04:33PM	Homology Medicines Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Aug-14-23 04:20PM	Homology Medicines: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Jul-27-23 04:05PM	Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU (GlobeNewswire) -8.74% +41.49%
04:01PM	Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU (GlobeNewswire)
Jul-06-23 11:17AM	12 Best Nano Cap Stocks To Buy Now (Insider Monkey) -5.02%
May-16-23 08:00AM	Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting (GlobeNewswire)
May-11-23 05:35PM	Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:25PM	Homology Medicines: Q1 Earnings Snapshot (AP Finance)
04:05PM	Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-03-23 07:30AM	Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting (GlobeNewswire) +5.71%
Mar-27-23 05:52AM	BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last? (Zacks)
Mar-15-23 04:01PM	Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting (GlobeNewswire) -5.61%
Mar-09-23 06:45PM	Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -9.46% -8.21%
04:05PM	Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
08:00AM	Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer (GlobeNewswire)
Mar-02-23 07:30AM	Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference (GlobeNewswire) -8.23%
Feb-24-23 05:31AM	Homology Medicines (NASDAQ:FIXX) shareholders have endured a 90% loss from investing in the stock three years ago (Simply Wall St.) -13.12%
Feb-22-23 04:01PM	Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium Meeting (GlobeNewswire) +19.40%
Jan-05-23 09:25AM	Homology Medicines Provides Update From Gene Therapy Trials (Benzinga) +14.62%
Jan-04-23 04:01PM	Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs (GlobeNewswire) +8.33%
Nov-12-22 08:08AM	Homology Medicines Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-10-22 05:45PM	Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +6.38%
04:07PM	Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights (GlobeNewswire)
Oct-27-22 09:00AM	Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting (GlobeNewswire)
Oct-06-22 08:30AM	Homology Medicines to Participate at Upcoming Conferences (GlobeNewswire)
Sep-27-22 08:15AM	Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures (GlobeNewswire) +5.26%
Sep-08-22 11:05AM	The Petri Dish: Homology gets new CEO amid shakeup; two Boston firms join 'pandemic readiness' lobby (American City Business Journals)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morrison Jodie Pope	CEO	Oct 06 '26	Sale	8.32	3,221	26,798	340,038	Oct 14 05:30 PM
Kalowski Lee	CFO and President	Oct 06 '26	Sale	8.32	1,301	10,824	137,170	Oct 14 05:30 PM
Violette Shelia M.	Chief Scientific Officer	Oct 06 '26	Sale	8.32	917	7,629	126,854	Oct 14 05:30 PM
Morrison Jodie Pope	CEO	Aug 25 '26	Sale	16.56	9,845	163,033	343,259	Aug 27 04:10 PM
Kalowski Lee	CFO and President	Aug 25 '26	Sale	16.56	3,972	65,776	138,471	Aug 27 04:10 PM
Violette Shelia M.	Chief Scientific Officer	Aug 25 '26	Sale	16.56	2,798	46,335	127,771	Aug 27 04:10 PM
Manke Isaac	Director	Jun 30 '26	Option Exercise	2.80	53,521	149,859	53,521	Jul 02 04:30 PM
Xu Diyong	Director	May 28 '26	Buy	8.00	1,875,000	15,000,000	3,502,987	Jun 01 09:15 PM
ORBIMED ADVISORS LLC	Director	May 28 '26	Buy	8.00	1,875,000	15,000,000	3,502,987	Jun 01 09:13 PM
Kalowski Lee	CFO and President	Feb 25 '26	Sale	4.51	3,995	18,035	35,943	Feb 27 07:00 PM
Morrison Jodie Pope	CEO	Feb 25 '26	Sale	4.51	9,896	44,675	89,104	Feb 27 07:00 PM
Violette Shelia M.	Chief Scientific Officer	Feb 25 '26	Sale	4.51	2,815	12,708	55,569	Feb 27 07:00 PM
Morrison Jodie Pope	CEO	Dec 02 '25	Sale	3.46	22,506	77,871	99,000	Dec 04 07:00 PM
Kalowski Lee	CFO and President	Dec 02 '25	Sale	3.46	9,072	31,395	39,938	Dec 04 07:00 PM
JODIE MORRISON	Officer	Dec 02 '25	Proposed Sale	3.46	22,506	77,871		Dec 02 04:29 PM
LEE KALOWSKI	Officer	Dec 02 '25	Proposed Sale	3.46	9,072	31,395		Dec 02 04:05 PM

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David S. Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

CEO & DirectorMs. Jodie Pope Morrison

CFO & PresidentMr. Lee H. Kalowski M.B.A.

Co-founderDr. Shelia M. Violette Ph.D.

Senior VP & Head of PeopleMr. David Appugliese J.D.

Chief Business OfficerMs. Maria Marzilli M.P.H.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QTTB

Q32 Bio Inc

Upgrade your Finviz experience